Ventures Fund V. General Partner Llc Flagship serves as Executive at Denali Therapeutics Inc., where they oversee executive responsibilities. Since joining the company, Ventures Fund V. General Partner Llc Flagship has executed 14 insider transactions totaling $6.0M, demonstrating a bearish approach to their equity position. Their most recent transaction on May 26, 2023 involved selling 9,330 shares valued at $58.1K.
Ventures Fund V. General Partner Llc Flagship currently holds 1,425,334 shares of Denali Therapeutics Inc. (DNLI), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Ventures Fund V. General Partner Llc Flagship has been a net seller of DNLI stock. They have purchased $2.5M and sold $3.5M worth of shares.
Ventures Fund V. General Partner Llc Flagship's most recent insider trade was on May 26, 2023, when they sold 9,330 shares at $6.23 per share.
Get notified when new Form 4 filings are submitted
| $6.23 |
| Discretionary |
| May 25, 2023 | SANA | $83.4K | Sale | 13,127 | $6.35 | Discretionary |
| May 25, 2023 | SANA | $649.3K | Sale | 102,245 | $6.35 | Discretionary |
| May 24, 2023 | SANA | $260.0K | Sale | 39,580 | $6.57 | Discretionary |
| May 24, 2023 | SANA | $2.0M | Sale | 308,290 | $6.57 | Discretionary |
| Oct 16, 2020 | CDAK | $0 | Conversion | 543,686 | $N/A | Discretionary |
| Oct 16, 2020 | CDAK | $0 | Conversion | 543,686 | $N/A | Discretionary |
| Oct 16, 2020 | CDAK | $0 | Conversion | 338,630 | $N/A | Discretionary |
| Oct 16, 2020 | CDAK | $0 | Conversion | 338,630 | $N/A | Discretionary |
| Oct 16, 2020 | CDAK | $0 | Conversion | 95,861 | $N/A | Discretionary |
| Oct 16, 2020 | CDAK | $0 | Conversion | 95,861 | $N/A | Discretionary |
| Oct 16, 2020 | CDAK | $2.5M | Purchase | 165,000 | $15.00 | Discretionary |
| Dec 12, 2017 | DNLI | $0 | Conversion | 8,606,249 | $N/A | Discretionary |